Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1744
mi
from
Knoxville, TN
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1744
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 3777
mi
from
Amarillo, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 3777
mi
from
Amarillo, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1440
mi
from
Arlington, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1440
mi
from
Arlington, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 014
mi
from
Austin, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 014
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site
mi
from
Houston, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1357
mi
from
Hurst, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1357
mi
from
Hurst, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1826
mi
from
Plano, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1826
mi
from
Plano, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1269
mi
from
Tomball, TX
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1269
mi
from
Tomball, TX
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 125
mi
from
Abingdon, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 125
mi
from
Abingdon, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 117
mi
from
Lynchburg, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 117
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative site 031
mi
from
Norfolk, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative site 031
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 020
mi
from
Richmond, VA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 020
mi
from
Richmond, VA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1870
mi
from
Tacoma, WA
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1870
mi
from
Tacoma, WA
Click here to add this to my saved trials
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated:  11/4/2015
Forest Investigative Site 1177
mi
from
Vancouver,
Efficacy, Safety, and Tolerability of Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-38)
A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of 2 Doses of Aclidinium Bromide Compared With Placebo for 12 Weeks in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease Followed by a 40-Week Evaluation of the Higher Aclidinium Bromide Dose
Status: Enrolling
Updated: 11/4/2015
Forest Investigative Site 1177
mi
from
Vancouver,
Click here to add this to my saved trials
Consequences of Nocturnal and Daytime Hypoxemia in COPD
Status: Enrolling
Updated:  11/13/2015
North Shore - LIJ Health System
mi
from
New Hyde Park, NY
Consequences of Nocturnal and Daytime Hypoxemia in COPD
Status: Enrolling
Updated: 11/13/2015
North Shore - LIJ Health System
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated:  11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated: 11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
Status: Enrolling
Updated:  11/16/2015
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
A Culturally Sensitive Values-Guided Aid for End of Life Decision-Making
Status: Enrolling
Updated: 11/16/2015
Michael E. Debakey VA Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Morgantown, WV
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Morgantown, WV
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Jasper, AL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Mobile, AL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Mobile, AL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Los Angeles, CA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Clearwater, FL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Ormond Beach, FL
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Lawrenceville, GA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Lawrenceville, GA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Topeka, KA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Madisonville, KY
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Lafayette, LA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Lafayette, LA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
New Orleans, LA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
St. Louis, MO
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Charlotte, NC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Elizabeth City, NC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Elizabeth City, NC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Cincinnati, OH
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Medford, OR
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Beaver, PA
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Beaver, PA
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Easley, SC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Easley, SC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Spartanburg, SC
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated:  11/19/2015
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
A Multi-center Trial Comparing the Efficacy and Safety of GSK573719/GW642444 With GSK573719 and With Tiotropium Over 24 Weeks in Subjects With COPD
Status: Enrolling
Updated: 11/19/2015
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Status: Enrolling
Updated:  11/30/2015
Washington DC VA Medical Center
mi
from
Washington,
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)
Status: Enrolling
Updated: 11/30/2015
Washington DC VA Medical Center
mi
from
Washington,
Click here to add this to my saved trials
TOPIC Trial for COPD
A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)
Status: Enrolling
Updated:  11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
TOPIC Trial for COPD
A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)
Status: Enrolling
Updated: 11/30/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
South Texas Veterans Health Care System
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
Puget Sound Veterans Administration Health Care System
mi
from
Seattle, WA
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
Puget Sound Veterans Administration Health Care System
mi
from
Seattle, WA
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated:  12/1/2015
Univ of Washington
mi
from
Seattle, WA
Chronic Obstructive Pulmonary Disease (COPD) Activity: Serotonin Transporter (SERT), Cytokines and Depression (CASCADE Study)
Depression and Functional Outcomes in COPD: Impact of Genetics and Inflammation
Status: Enrolling
Updated: 12/1/2015
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Status: Enrolling
Updated:  12/2/2015
UCLA
mi
from
Los Angeles, CA
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Status: Enrolling
Updated: 12/2/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Status: Enrolling
Updated:  12/2/2015
UCSF
mi
from
San Francisco, CA
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
Status: Enrolling
Updated: 12/2/2015
UCSF
mi
from
San Francisco, CA
Click here to add this to my saved trials
COPD Assessment and Management Bundle Versus Usual Care
Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD
Status: Enrolling
Updated:  12/4/2015
Univ of Illinois
mi
from
Chicago, IL
COPD Assessment and Management Bundle Versus Usual Care
Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD
Status: Enrolling
Updated: 12/4/2015
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.440.1015 Boehringer Ingelheim Investigational Site
mi
from
Jasper, AL
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01040 Boehringer Ingelheim Investigational Site
mi
from
Stamford, CT
Click here to add this to my saved trials
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/10/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)
A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/10/2015
205.452.01011 Boehringer Ingelheim Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials